Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137411 | 0.89 | LTB4R2 (0.40) | LTB4R2CSNK1DBMP1CNR2MAPT | |
| SCHEMBL20570505 | 0.89 | LTB4R2 (0.42) | LTB4R2CSNK1DPPARGBMP1 | |
| SCHEMBL20151838 | 0.88 | PPARG (0.39) | PPARGMAPTBCHEACHE | |
| SCHEMBL20166820 | 0.83 | ALOX5 (0.40) | CETPDHFRPPARG | |
| SCHEMBL20137060 | 0.79 | MGLL (0.41) | CETPDHFRPPARG | |
| SCHEMBL20137009 | 0.79 | MGLL (0.36) | CETPDHFRPPARGMAPT | |
| SCHEMBL20166910 | 0.79 | KDM4E (0.39) | CETPPPARG | |
| SCHEMBL20137127 | 0.79 | BMP1 (0.37) | LTB4R2CSNK1DBMP1CNR2MAPT | |
| SCHEMBL20137037 | 0.79 | KDM4E (0.38) | CETPDHFRPPARGMAPT | |
| SCHEMBL20150068 | 0.79 | TSPO (0.39) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541821-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10093635-B2 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | LTB4R2 1924/4885CETP 1116/4885DHFR 2914/4885 |
| US-10093635-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | LTB4R2 1924/4885CETP 1116/4885DHFR 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.